ArticleProceedings of the National Academy of Sciences of the United States of America2025
Mutant
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Two Decades ofCancers · 2026Review
- Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Takashi Sakamoto *Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.ORCID 0000-0001-8868-1661
Julie Leca *Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Xin Zhang *Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Cem Meydan *Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065.
Jonathan Foox *Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065.
Parameswaran RamachandranPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Liam D HendriksePrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Wenjing ZhouPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Thorsten BergerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Jerome FortinPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Steven M ChanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Ming-Feng ChiangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Satoshi InouePrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Wanda Y LiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Mandy F ChuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Gordon S DuncanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Andrew WakehamPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
François LemonnierPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Chantal TobinPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Ryan McwilliamPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Isabelle ColonnaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Christophe BontouxPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Soode Moghadas JafariPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Robert L BowmanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Brandon NicolayAgios Pharmaceuticals, Cambridge, MA 02139.
Sebastien RonseauxAgios Pharmaceuticals, Cambridge, MA 02139.
Rohini NarayanaswamyAgios Pharmaceuticals, Cambridge, MA 02139.
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Ari M MelnickDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY 10021.
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065.ORCID 0000-0002-1850-1642
Mark D MindenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.ORCID 0000-0002-9089-8816
Tak W MakPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.ORCID 0000-0001-6766-861X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MProject 3: Targeting PRMT5 in Mantle Cell LymphomaP01CA214274 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER · 2018 to 2022
$8.9MClinical and Molecular Heterogeneity in the Myelodysplastic SyndromesR01CA249054 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MASON, CHRISTOPHER EDWARD, PARK, CHRISTOPHER Y · 2020 to 2024
$3.5MMetagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantationR01AI151059 · NIAID · CORNELL UNIVERSITY · PI DADHANIA, DARSHANA, DE VLAMINCK, IWIJN · 2020 to 2024
$3.4MThe Spatiotemporal Landscape of the Human Brain EpitranscriptomeR01MH117406 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI MASON, CHRISTOPHER EDWARD · 2018 to 2022
$3.3MInterrogating oncogene-dependency and mutation order in FLT3 mutant AMLK99CA248460 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOWMAN, ROBERT LYLE · 2020 to 2021
$297kCanadian Government | Canadian Institutes of Health Research (CIHR) RN482269 - 480701Cancer Research Institute (CRI) N/AHHS | National Institutes of Health (NIH) P01CA214274HHS | NIH | National Cancer Institute (NCI) 2P30CA008748-48HHS | NIH | National Cancer Institute (NCI) K99CA248460Innovation and Technology Commission (ITC) N/ALeukemia and Lymphoma Society (LLS) 7029-22Leukemia and Lymphoma Society (LLS) LLS 9238-16 LLS-MCL-982MEXT | Japan Society for the Promotion of Science (JSPS) 20K17377NCI NIH HHS K99 CA248460NCI NIH HHS P01 CA214274NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA249054NIAID NIH HHS R01 AI151059NIMH NIH HHS R01 MH117406Starr Cancer Consortium I7-A765 I9-A9-071 I13-0052The Pershing Square Sohn Cancer Research Alliance R01AI151059Vallee Foundation (The Vallee Foundation) R01MH117406WorldQuant Foundation R01CA249054
Abstract
In human acute myeloid leukemia (AML), mutations of isocitrate dehydrogenase-1 (
Indexed as
fms-Like Tyrosine Kinase 3Isocitrate DehydrogenaseLeukemia, Myeloid, AcuteMutationNuclear ProteinsAnimalsGene Knock-In TechniquesHumansMiceNucleophosminFLT3 protein, humanFlt3 protein, mousefms-Like Tyrosine Kinase 3IDH1 protein, humanIdh1 protein, mouseIsocitrate DehydrogenaseNPM1 protein, humanNpm1 protein, mouseNuclear ProteinsNucleophosminacute myeloid leukemiaFLT3IDH1NPM1preclinical mouse model
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.